Sep 21, 2026, 5:06 PM EDT · 25 days ago These beaten-down stocks could bounce back in January, if history is any guide ADCT BRCB CAPR EYPT IVVD LENZ MVST
2026-09-08T09:10:19.000Z · 5 weeks ago Upstream Bio presents results from VALIANT trial at ERS Congress
Sep 8, 2026, 3:30 AM EDT · 5 weeks ago Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
2026-09-01T13:15:32.000Z · 6 weeks ago Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps
Sep 1, 2026, 7:00 AM EDT · 6 weeks ago Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
2026-06-14T20:55:54.000Z · 4 months ago Upstream Bio presents new responder analyses from VIBRANT trial of verekitug
Jun 14, 2026, 10:00 AM EDT · 4 months ago Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
2026-06-12T08:55:22.000Z · 4 months ago Upstream Bio downgraded to Neutral from Overweight at JPMorgan
Jun 8, 2026, 7:00 AM EDT · 4 months ago Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Jun 3, 2026, 7:00 AM EDT · 4 months ago Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-18T15:35:26.000Z · 5 months ago Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
May 18, 2026, 11:30 AM EDT · 5 months ago Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
May 13, 2026, 7:00 AM EDT · 5 months ago Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-17T11:07:21.000Z · 6 months ago Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
Apr 17, 2026, 7:00 AM EDT · 6 months ago Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
2026-03-27T10:45:28.000Z · 6 months ago Upstream Bio downgraded to In Line from Outperform at Evercore ISI
Mar 26, 2026, 7:00 AM EDT · 6 months ago Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 1, 2026, 9:45 AM EST · 7 months ago Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Feb 26, 2026, 7:00 AM EST · 7 months ago Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Feb 25, 2026, 7:00 AM EST · 7 months ago Upstream Bio to Participate in Upcoming March Investor Conferences
Feb 11, 2026, 6:00 AM EST · 8 months ago Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Feb 10, 2026, 6:00 PM EST · 8 months ago Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
Jan 5, 2026, 7:00 AM EST · 9 months ago Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nov 25, 2025, 7:00 AM EST · 10 months ago Upstream Bio to Participate in Upcoming December Investor Conferences
Nov 5, 2025, 7:00 AM EST · 11 months ago Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
Oct 31, 2025, 7:00 AM EDT · 11 months ago Upstream Bio to Participate in Upcoming November Investor Conferences
Sep 30, 2025, 4:15 AM EDT · 1 year ago Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
Sep 9, 2025, 7:00 AM EDT · 1 year ago Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Sep 2, 2025, 6:00 AM EDT · 1 year ago Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Sep 1, 2025, 5:00 PM EDT · 1 year ago Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Aug 6, 2025, 7:00 AM EDT · 1 year ago Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Jul 8, 2025, 7:00 AM EDT · 1 year ago Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
Jun 15, 2025, 7:45 AM EDT · 1 year ago Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Jun 5, 2025, 7:00 AM EDT · 1 year ago Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Jun 4, 2025, 7:00 AM EDT · 1 year ago Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 6, 2025, 7:00 AM EDT · 1 year ago Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
Mar 12, 2025, 7:00 AM EDT · 1 year ago Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Feb 25, 2025, 8:00 AM EST · 1 year ago Upstream Bio to Present at Upcoming March Investor Conferences
Oct 15, 2024, 4:15 PM EDT · 2 years ago Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Oct 11, 2024, 12:49 PM EDT · 2 years ago Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut
Oct 10, 2024, 7:35 PM EDT · 2 years ago Upstream Bio Announces Pricing of Upsized Initial Public Offering